5月20日,三生国健发布公告称,公司及关联方三生制药和沈阳三生制药有限责任公司,共同授予辉瑞在许可区域(即除中国大陆以外的其他国家和地区)及领域(即人类和兽医用途的所有治疗、诊断及预防适应症)独家开发、生产和商业化许可产品707项目(即同时靶向PD-1和VEGF的双特异性抗体产品)的权利。根据协议,辉瑞将支付12.5亿美元的不可退还和不可抵扣首付款,以1亿美元对价在《许可协议》生效日根据约定价格...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.